Es Farmacia Online Thu, 02 Dec 2021 20:37:10 +0000 en-US hourly 1 Es Farmacia Online 32 32 Virtual care companies rush to facilitate access to Covid-19 antivirals Thu, 02 Dec 2021 20:23:30 +0000

As two new antiviral pills for Covid-19 are approaching emergency clearance, experts fear that a lack of public health infrastructure – especially easy access to rapid tests and quickly filled prescriptions – will prevent them from make a significant dent in the pandemic.

“We know that these antivirals are going to have a window of opportunity where they are most effective, and it can be difficult to get an appointment and get a prescription,” said Amesh Adalja, infectious disease specialist, researcher. principal at the Johns Hopkins Center. for health security.

Virtual care companies believe they could speed up the process of giving antivirals to patients within three to five days of symptom onset, when they are most effective. This week, digital health company Truepill announced that it will soon launch a platform to support telehealth consultations, prescriptions and overnight delivery of new drugs, from Merck and Pfizer, when they are authorized. . Carbon Health, which has both physical clinics and virtual care, plans to expand its Covid acute care program to include oral antivirals. And the direct-to-consumer company Ro says it has the ability to prescribe and deliver the drugs and expects to make them available through its platform.


“I think there might be a great opportunity here to take advantage of all the telehealth that has developed during the pandemic, and was going on even before the pandemic, to be able to put prescriptions in people’s hands. much faster than the traditional route. ” said Adalja.

But that opportunity depends on getting all the other pieces in place at the right time. For the pills to reach their full potential, people need to be able to procure and pay for tests, receive their results quickly, and immediately connect with a healthcare provider if they test positive for Covid.


If all of these steps go as planned, online platforms, due to their distributed workforce of virtual providers, could get prescriptions faster while still allowing HIV-positive patients to self-quarantine. When a patient registers online for Carbon Health’s Covid-19 program, “we make sure they receive a thorough virtual assessment within 24 hours of symptom onset,” said the medical director of program development Aaron Weinberg, also national director of Carbon for Research. “The clock starts as soon as someone contacts us.”

Once patients meet with a Carbon Health provider and receive a positive test result, they may be given a prescription for monoclonal antibodies, a pulse oximeter to self-monitor their symptoms, or soon, a prescription for antivirals.

Truepill offers an even more explicit speed guarantee, with the intention of offering its teleconsultation and delivery services as a plug-and-play tool for existing healthcare systems, providers and payers, said Andy Rink, vice president of telehealth at Truepill. “We will essentially allow any patient who has tested positive for Covid and qualifies for these drugs under the [emergency use authorization] guidelines for getting the drug within 24 hours, ”he said.

How quickly digital pharmacies can get antivirals to a patient’s door will depend greatly on supply. Drugs, like vaccines and other Covid-19 therapies, will be distributed state by state as needed. To ensure prompt delivery after a telemarketer has prescribed the medication, Truepill will arrange for access in one of two ways: dispatching them overnight via one of the company’s own pharmacy centers, or arranging the pickup or delivery to a retail pharmacy, using publicly available information to determine which locations have drugs in stock. “We can take that information and pass it on to the supplier at the time of that visit, so that we can send it to the right place, the first time,” Rink said.

Truepill plans to complete its platform within two weeks and is in discussions with groups that may implement it. “We have groups of vendors who are interested in taking our existing solution and using it for their patients, even patients who already have a primary care physician,” said Rink – primarily with the benefit of securing a supply. reliable in medicine. They also talk to payers, employer groups and existing direct-to-consumer businesses.

Until these partnerships are solidified, it is unclear what the impact will be on increasing access in underserved patient groups – particularly the elderly and low-income people, who are less likely to have access to or use telemedicine. Telehealth has also been used less among non-white, uninsured and rural patients.

“I’m concerned that we have this tendency to herald breakthroughs in technology, while really preparing for a disruption in delivery to those who will need it most,” said Alyssa Bilinski, public health policy expert at the University. Brown.

It is possible that telehealth companies could, if not increase access for the most underserved patients, ease the burden on some providers in person, or reduce wait times for some patients. Direct-to-consumer drug companies like Ro, Nurx, and Hims & Hers – many of whom began by providing convenient online prescriptions for erectile dysfunction or birth control drugs – have increasingly expanded their offerings, including Covid-19 testing and added telehealth services. These companies could capitalize on their own network of telemarketers to support access to antivirals, or deploy a platform like Truepill’s.

“The companies that have been able to do it with other drugs, lifestyle drugs, I think they’re perfectly ready to do it,” Adalja said.

But each of these pathways to digital prescription and delivery could face obstacles. Not all virtual care networks have licensed telemarketers in every state; a person looking for a quick prescription may find themselves in a bind when they realize that a platform is not serving them. And while the platforms typically require users to complete an intake survey that asks about indications for antiviral drugs, patients with complex medical histories should be especially careful to ensure that a new telemarketer is taking. take into account any contraindication or potential drug interaction.

“Given their potential advantage in terms of access, one might see direct-to-consumer telemedicine companies playing a bigger role,” Mehrotra said. “However, I suspect the vast majority of people will still go to their regular PCP or go to a local emergency care or retail center.”

Primary care offices are also able to write prescriptions after virtual visits, of course. In a study led by Michael Anne Kyle, a postdoctoral researcher in the Department of Health Care Policy at Harvard Medical School, researchers found that many primary care offices offered testing and virtual visits during the pandemic. “But the wait times to get an appointment were usually out of the window… needed to start the antivirals,” Kyle wrote in an email.

Rink said that Truepill’s platform will allow users to order a home test online, but acknowledged that “given the five-day window, it will be difficult to do all of that – take the test, do it. deliver, have the visit, get the drug. So patients who turn to virtual care companies for an antiviral prescription will likely have had an antigen test at home. This means that the biggest beneficiaries of virtual platforms could be the ones who had the means and the capacity to stock up on these tests. “We see a lot of people ordering tests in advance to have them at home,” Rink said.

In a bid to increase access to testing, the Biden administration has said it will soon require private insurers to reimburse Americans for the cost of rapid home antigen testing. But access can still present a challenge for patients who don’t have the $ 30 or so to pay for a test up front, or for those who can’t find tests on the shelves.

If telehealth is to play a role, then it should only be part of a systemic effort to enable access to rapid testing, diagnosis and treatment with new antivirals.

“So much less attention was paid to the full stunt of stages,” Bilinski said. “It starts with educating people to get tested, and then take the test and the quick turnaround time of the test, but then knowing that you want to ask for a prescription, have some sort of consultation with someone who can prescribe, and then have this prescription filled. . “Any break in this chain of events could be the one preventing the pills from reaching their full impact.

Lyme disease treatment market to expand at 6.3% CAGR; Substantial Clinical Research For Effective Treatment To Amplify Market Growth, TMR Study Finds Thu, 02 Dec 2021 12:30:00 +0000

ALBANY, NY, December 2, 2021 / PRNewswire / – The increasing prevalence of Lyme disease in developed countries that receive funding from non-medical organizations to develop the treatment is fueling the growth of the Lyme disease treatment market. Lyme disease is the most common vector-borne disease in the United States with nearly half a million cases reported each year. According to the Centers for Disease Control and Prevention, 20,000 to 30,000 confirmed cases of Lyme disease are reported in the United States each year. The number of Lyme disease cases has also increased steadily in Europe, reports the World Health Organization.

Lyme disease is prevalent in humans and animals, and growing affection towards pets is leading to increased transmission of Lyme disease. Lyme disease is transmitted by bacteria and transmitted to humans through the bite of infected blacklegged ticks. Headaches, fever, and rashes are common symptoms of Lyme disease, which can spread to the heart, joints, and neurotic system if not treated in time.

Request Lyme Disease Treatment Market Research Report Brochure –

The factors are assessed for the Lyme disease treatment market, which is expected to reach US $ 3 billion by 2031.

Lyme Disease Treatment Market – Key Findings of the Report

Initiatives to develop a new line of treatment for the early detection of ongoing diseases

Clinical research such as that based on a novel cytokine immunoassay for earlier and improved examination of Lyme disease is underway in the Lyme disease treatment market. This involves the use of advanced technologies for rapid point-of-care treatment of Lyme disease. New ways to identify Lyme disease, early stage examination, precise disease staging, and indications for successful treatment are other goals of clinical research initiatives in the disease treatment market. of Lyme.

Request for Analysis of the Impact of COVID-19 on the Lyme Disease Treatment Market –

Clinical trials funded by medical organizations to study the effectiveness of prolonged antibiotic therapy for the treatment of Lyme disease are underway. Nonetheless, innovations for simple and effective Lyme disease treatments have been adopted by major players in the Lyme disease treatment market for the enhancement of the disease treatment portfolio. For example, initiatives by the National Institutes of Health in several areas of research for the treatment of Lyme disease show that most people recover within weeks of completing oral therapy when they are treated soon after symptoms appear.

Risk of secondary disease mortality in dogs receives attention

The United States has a high number of Lyme disease cases in dogs, while other geographies are expected to see more ticks carrying bacteria in dogs. Symptoms of Lyme disease also vary in animals without symptoms.

TMR offers customized market research services that help clients gain insight into their required business scenario when syndicated solutions are not enough, Custom Research Request –

Loss of appetite, pain or swelling, fever and swollen lymph joints are the first signs of lymphatic disease in animals, which, if left untreated, can lead to serious damage to the heart. , nervous system or kidneys. Lyme disease affecting the organs is the second most common symptom in dogs and is usually fatal. This explains the attention paid to Lyme disease treatment in pet owners.

Lyme Disease Treatment Market – Growth Drivers

  • Rising Pet Ownership and Spending on Veterinary Care Boost Lyme Disease Treatment Market
  • Clinical research supported by government organizations and large companies to develop treatment for Lyme disease prevalent in humans and animals is fueling growth in Lyme disease treatment market

Lyme Disease Treatment Market – Key Players

Some key players operating in the Lyme disease treatment market are GlaxoSmithKline plc, Novartis AG, Almirall LLC, Boehringer Ingelheim International GmbH, Lupine Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Orion Corporation, F. Hoffmann-La Roche Ltd ., Mayne Pharma, Galderma Laboratories LP, Chartwell Pharmaceuticals and Perrigo Company plc.

Buy Lyme Disease Treatment Market Report –

The Lyme disease treatment market is segmented as follows;

Lyme Disease Treatment Market, By Treatment Type

  • Medication
    • Antibiotics
      • Cephalosporin
      • Tetracycline
      • Macrolides
      • Others
    • NSAIDs
    • Others
  • Tick ​​removal

Lyme Disease Treatment Market, By Bacteria Type

  • Borrelia burgdorferi
  • Borrelia mayonii
  • Borrelia afzelii
  • Borrelia garinii
  • Others

Lyme Disease Treatment Market, By Administration

Lyme Disease Treatment Market, By Application

Lyme Disease Treatment Market, By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Lyme Disease Treatment Market, By Region

  • North America
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • The rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa

The modernization of healthcare in terms of infrastructure and services has pushed the healthcare sector to new heights, Stay up to date with Latest research reports on the health industry through market research on transparency:

Von Willebrand Disease Treatment Market: Research and development activities are expected to play a significant role in increasing the growth of the global Von Willebrand Disease Treatment market during the assessment period. The arrival of new therapies and treatment for von Willebrand disease, as a result of research programs and initiatives, is expected to significantly boost the global von Willebrand disease treatment market.

FFPE Tissue Samples Market: This report analyzes the current scenario and future prospects of the global FFPE Tissue Samples Market. FFPE is a form of preparation and storage of biopsy specimens that assists in diagnostic / drug development, experimental research, and examination.

Herbal Vaccines Market: Global Herbal Vaccines Market for the historical period of 2017-2019 and forecast period of 2021-2031, increasing incidence of infections, government initiatives for expansion of Vaccine coverage and government funding for vaccine development are expected to boost the global herbal vaccine market in the near future

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our proprietary blend of quantitative forecasting and trend analysis provides forward-looking information to thousands of decision makers. Our experienced team of analysts, researchers and consultants use proprietary data sources and various tools and techniques to collect and analyze information.

Our data repository is continually updated and reviewed by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analytical capacity, Transparency Market Research uses rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

For more information on research on major industries, visit our YouTube channel and click Subscribe for the future update –

Sir. Rohit Bhisey
Market research on transparency
State Tower,
90 State Street,
Office 700,
Albany NY – 12207
United States
United States – Canada Toll Free: 866-552-3453
E-mail: [email protected]
Follow us: Twitter | LinkedIn
Browse public relations –

SOURCE Transparency Market Research

Source link

Efficacy of Covishield in fully vaccinated 63 pc: Study Thu, 02 Dec 2021 03:37:40 +0000

The effectiveness of Covishield’s vaccine against COVID-19 infection in fully vaccinated individuals was found to be 63% between April and May, when the second wave was at its peak in India, according to a new study.

It was published in The Lancet Infectious Diseases and included a comparison between 2,379 cases of confirmed infection with SARS-CoV-2 and 1,981 controls.

The vaccine’s efficacy against SARS-CoV-2 infection in fully vaccinated individuals was found to be 63%.

The Ministry of Science and Technology shared the study in an official statement.

More importantly, the scientists also observed that the spike-specific T cell responses were conserved against both the delta variant and wild-type SARS-CoV-2. Such cellular immune protection could compensate for the decrease in l ‘humoral immunity against virus variants and prevent moderate to severe illness and the need for hospitalization,’ the study said.

The ministry said the study provides comprehensive data on the vaccine’s real-world efficacy and immunological response to vaccination that should help guide policy.

A multi-institutional team of Indian researchers led by the Translational Health Science and Technology Institute (THSTI) evaluated the actual effectiveness of the Covishield vaccine during the outbreak of SARS-CoV-2 infection between April and May 2021, in India.

They also evaluated neutralizing activity and cellular immune responses against the variants in healthy vaccinated individuals to understand the mechanisms of protection.

Source link

Women suffering from a lack of use of their favorite HIV drugs Wed, 01 Dec 2021 18:09:13 +0000

In July 2019, the World Health Organization (WHO) indicated dolutegravir for all adolescents and adults living with HIV. This recommendation came after a safety signal in May 2018 suggesting that exposure to dolutegravir at conception was associated with neural tube defects in the infant.

Although the WHO has reviewed additional evidence and weighed the risks and benefits before making its recommendation, absorption of dolutegravir remains low in women living with HIV.

Investigators conducted an observational cohort study of 87 sites that started using dolutegravir in 11 low- and middle-income countries. The sites included participated in the International Epidemiological Databases for AIDS Assessment (IeDEA) of the Asia-Pacific, Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet) and the regions of Central, East and Africa. southern.

The study, published in Annals of Internal Medicine, included 134,672 patients aged 16-49 who received care from January 2017 to March 2020. Participants had just started or were on existing antiretroviral therapy.

At the end of the follow-up period, absorption of dolutegravir in women aged 16 to 49 was 29.4%, compared to 57.7% for men in this age group. This gap in dolutegravir use was larger in countries that implemented the drug before the safety signal and initially had restrictive policies, as opposed to countries that recommended dolutegravir after the WHO recommendation.

Professor CUNY Denis Nash, lead author of the study, discussed the implications of the findings: “The large disparities quantified by our study mean that the missed or delayed opportunities to improve HIV treatment outcomes could be substantial in the long term if they are not corrected quickly. We need faster and more robust pharmacovigilance surveillance both before and after safety signals, which is important to reliably detect, characterize and quantify adverse events, and to rigorously inform decisions. of implementation regarding the use of pharmaceuticals on a large scale.

Dolutegravir has the potential to help eradicate HIV as a global public health threat. It has a superior efficacy profile and reduces the transmission of HIV during sex, between needle-sharing partners and in utero.

The study concluded: “Although this disparity was anticipated due to country-level access restrictions, the results highlight its extent and initial persistence. “

Source link

Tata Engines | Tata Group Companies | M&M: Why digitization remains the most powerful theme for the Indian market Wed, 01 Dec 2021 03:57:00 +0000 “We think Tata Motors and M&M are two very independent segments and in a way that gives us a very holistic and comprehensive exposure to the whole four-wheel space in automobiles,” said Nilesh shah, Managing Director and CEO, Imagine the capital.

The consumer spending frenzy could be halted if interest rates rise and inflation returns. We could go through this dangerous time where growth is challenged and inflation persists, which means a rate hike, then the reversal begins. Isn’t that the biggest risk?
It is more a source of volatility than the genesis of risk. I think interest rates could go up 25 to 50 basis points, but I don’t see a significant rate hike here in India. This is also the case at the global level. Yet policymakers continue to believe that low interest rates are essentially the way to go and that is the way to bring strength.

In India, fortunately, we are not quite a leveraged economy yet and Indian households and families are not yet so in debt. Today, mortgage interest rates are 6.5-6.75%. They could go as high as 7-7.25% but will that deter an individual and a family from taking out a mortgage to buy the next house? I do not think so.

Also, I think revenge buying, revenge travel, pent-up demand still exists, so I don’t see any significant risk to the overall business environment with a moderate rate hike. I still think that if there is a rate hike it will be a bit moderate and we will benefit from an environment of low interest rates and high liquidity.

So you’re basically saying trade unlock can stay safe when it comes to revenge shopping, revenge travel, revenge dinners. The last time we spoke you said you took a leap of faith and started owning platform companies. Since then, a lot has happened and the IRCTC stock has corrected. We saw what happened with the IPO of Paytm. How would you approach this?
I still believe that digitization is the most important or the most powerful theme. It has performed very well in the rest of the world markets, including the United States and China. This is something that will play out even in India. It’s started to play out, but we still think it’s just the start.

That said, it should not be forgotten how tolerant public markets are towards companies reporting losses. I think the next few quarters are going to be very interesting. Good public markets continue to support loss-making platforms. The good thing today is that there are a lot of choices among platform companies or new age companies. There is a set of businesses there that are profitable and there is a set that is loss-making. So far, we only bet on for-profit companies that generate cash flow to fund this growth.

We haven’t invested in companies that continue to make losses yet, but who knows? Space is getting interesting and all of these companies are talking about a huge TAM (Total Addressable Market). As investors, apart from TAM, we also need to look at the MAT (Money After Transactions), that they have margins and generate money. So it’s going to be an interesting fight between TAM and MAT and that’s what we need to be careful about.

Also read: What stocks to buy, sell and hold as the market corrects 10%

You own ICICI Lombard. What do you think of Star Health’s IPO?
We’ve owned ICICI Lombard for quite some time and it’s a very interesting piece. We continue to love what ICICI Lombard is doing, especially in general health insurance, where it continues to be the biggest player with almost 8% market share and is obsessed with its performance targets. equity of around 20% and more.

Star Health Insurance is a very interesting piece. We are very constructive on health insurance and appreciate the fact that Star Health Insurance is a leader in this area. It has grown at a tremendous rate and, of course, health insurance continues to be relatively less penetrated. So we love this space.

It’s just that the valuations seem to be higher and therefore one would probably want to wait a while before investing in Star Health Insurance. Honestly, I don’t know when this opportunity arises, but I’ve generally seen over the years that even some of these new listings provide an opportunity to enter at a later stage, either when the market corrects itself or when specific companies having a bad quarter create an opportunity for one to invest.

I think Star Health Insurance is a great business and it’s a space to watch for someone who is really constructive in the long run.

You have Cipla and DRL. Have you added any health services to this pack? Diagnostic stocks are doing very well. Would you add it to your portfolio?
Not yet. We continue to love frontline pharmaceutical companies. We still think the next couple of years could be very exciting for them, given the kind of launches they have in regulated markets like the United States. We continue to love the big pharmaceutical companies. We do not own any of the diagnostics companies but we are eagerly awaiting the IPO of Pharmeasy. We think this is going to be an interesting space given that Pharmeasy also owns Thyrocare which is a diagnostic company. Plus, it means an online pharmacy today.

The media are reporting that they are also planning to be omnichannel and are starting to open stores. We will wait for Pharmaeasy’s IPO. In general, we like the online pharmacy space. It’s a huge market and it’s basically ready to be disrupted by some of these players online. It is a more interesting space than the autonomous diagnostic companies.

Month to date, have you had somewhere in the past month or reduced positions?
Yes, we have cropped positions. We kind of exited the position in Triveni Turbines which we bought a few months ago and which had seen a ferocious surge. Roughly a fair value went into the price. So we left Triveni Turbines. There are a few other positions where we reduced our holdings and looked at an opportunity like this.

Do you think the shift in perception within the Tata group of companies – Tata Power, Tata Motors, Tata Steel or for that matter TCS – is over?
In a way, the band really did perform and it seems like it’s best to roll on the Tata name. In the past, we have invested in Tata Elxsi which has worked very well. Of course we no longer have it. So it worked very well.

But in general a lot of the revaluation of PEs has happened and when I look at companies like Tata Consumer, TCS and Tata Elxsi, as an investor you can’t bet now on further expansion of PE to from those kinds of levels. The stock that we love the most now in Tata Group is Tata Motors. We think this is just the beginning of the story and over the next few years Tata Motors will play a pretty big role.

They seem to have basically every part that pulls well or should pull well – whether it’s an expected increase in CV cycle or a huge breakthrough in the EV space. They really seem to have the best of both worlds. I don’t think the share price at current levels takes into account future potential and the whole Tata Group pack, this is one of the stocks we love the most today.

The stock of Tata Motor went from Rs 350 to 550 after the agreement which valued the EV activity at 10 billion dollars. What could be the next trigger? Nilesh Shah: For a market as huge as India and for someone who is a trailblazer like the Tatas, if the EV strategy works really well, keep in mind that globally, the EV space has worked really well in the four wheel, passenger auto segment and that is exactly where they are going to be.
Of course, it has been different so far. We hear more noise on the EV two-wheeler space, but it clearly looks like the Tatas have a huge advantage or a leading edge over the EV touring car cycle. We think $ 10 billion is just the start. Keep in mind that they said this space was profitable and cash flow generated after the first two or three years. It is phenomenal for me.

Second, it is in the conventional passenger car sector that they have gained market share at the expense of other leaders and if this continues, then this sector which is honestly an overhang on Tata Motor’s stock, is going to act as a huge tailwind for the stock.

The third element is of course the expected rise in the CV cycle. The CV cycle has been pretty much moribund for the past two or three years and this is something that is expected to pick up over the next two or three years. If you are going to have so many activities related to manufacturing, mining and infrastructure, then you will see the CV request coming back. There, Tata Motors is the market leader.

I believe these three pillars – CVs, Conventional PVs, and Expected EVs – all together are tailwinds strong enough for Tata Motor’s stock not only to revalue, but also to grow based on huge growth in sales. benefits as well.

What about M&M because there have been new launches and a lot of talk about innovations?
M&M is an excellent proxy for remediation. What they’ve achieved in the last year or a year and a half is phenomenal and they’ve basically come out in a certain way or as we say in our lingo, they’ve had a stop loss for various companies. deficit and that was the first big step.

Two, of course, are the tractors and farm equipment, as one space has worked well and should continue to do well. Overall, we think M&M is a great type of investment for the next few years. It has strong outperformance potential and we also own M&M. We think Tata Motors and M&M are two very independent segments and in a way that gives us a very holistic and comprehensive exposure to the whole four-wheel space in automobiles.

An FDA panel to discuss Merck’s COVID-19 pill on Tuesday; here is what you need to know Tue, 30 Nov 2021 12:02:31 +0000

A Food and Drug Administration advisory group will meet on Tuesday to discuss a possible emergency authorization for the use of Merck’s antiviral drug to treat COVID-19.

The pill, developed in partnership with Ridgeback Biotherapeutics, aims to reduce serious illness and mortality in COVID-19 patients. Merck asked the FDA in October to approve the drug, named molnupiravir, for adults with mild to moderate COVID-19 infections who are at risk of hospitalization.

What did Merck’s updated research on the pill show?

On Friday, Merck released updated data, based on 1,433 unvaccinated patients, which showed its drug reduced hospitalizations and deaths by 30%. This is a significant decrease from preliminary data released last month, showing a 50% reduction based on 775 unvaccinated patients. Merck’s full data has not yet been published or peer reviewed.

The new findings have dampened some of the enthusiasm surrounding the oral treatment, which, if approved for emergency use, would be the first such antiviral pill used to treat COVID-19.

In its analysis of the pill, the FDA said scientists had identified some potential risks, including possible toxicity to developing fetuses and birth defects. The FDA will ask the advisory committee if the drug should ever be administered during pregnancy, the Associated Press reported.

The drug will not be used in children, the FDA said.

What do we know about another COVID-19 pill developed by Pfizer?

Rival pharmaceutical company Pfizer is also working on an antiviral pill, called paxlovid, to treat the virus. Initial results from the study of around 1,200 patients showed the drug reduced hospitalizations and deaths by 89%.

Pfizer has submitted paxlovid for FDA review, although it is not clear when the agency will review the drug. Like Merck, Pfizer has yet to release full data or subject it to peer review.

How would the COVID-19 pill help hospitals?

Oral antiviral treatment for COVID would provide an additional tool for healthcare providers trying to reduce the strain the virus places on hospitals.

“Right now, all of our proven effective therapies are drugs or IV treatments that we give to hospitalized people, or monoclonal antibodies, which have been shown to be very effective and effective in treating outpatients, but require an infusion. IV, ”said Dr. James Cutrell, associate professor of medicine in the Department of Infectious Diseases and Geographic Medicine at the University of Texas Southwestern Medical Center.

How do Merck and Pfizer COVID-19 pills work?

During clinical trials, patients receiving Merck treatment took a total of 40 tablets over the five days. Patients receiving Pfizer treatment took a total of 30 tablets over five days. Treatments should be started within five days of symptom onset.

Both drugs prevent the COVID-19 virus from replicating, but they do so at different points in the replication process.

Merck’s pill interferes with the way the virus copies its genetic material, causing mutations. “Eventually there are so many mistakes or mutations created that the virus somehow dies,” Cutrell said.

Pfizer’s treatment operates in a different part of the viral life cycle, instead interfering with an enzyme needed for replication. Treatment consists of two components, an experimental molecule and a medicine called ritonavir, which has been used in HIV patients before.

The molecule interacts with the virus while ritonavir prevents other enzymes from destroying it, Becker’s Hospital Review reported.

What are the limits of COVID-19 pills?

The new drugs, while potentially useful in preventing serious illnesses caused by COVID-19, have limitations, said Catherine Troisi, associate professor of epidemiology at the University of Texas Health Sciences Center at Houston.

Many times people infected with COVID-19 don’t know they have the virus until several days after symptoms start, meaning antiviral pills are unlikely to be effective by the time these people are treated.

Access to pills is also a concern. “If you have your primary care doctor and you can get it right away, then that’s great,” Troisi said. “But a lot of people don’t have that.”

If either pill is cleared for emergency use, there will still be questions about cost and availability, Cutrell said.

“These are all important issues that we will watch out for when the FDA panel looks at the data and then once we see what decision is made,” he said.

The Associated Press contributed to this report.

Left to right: Nurses Kelsey O'Meara, Noelle Hackfeld and Joanna Pless examined the oxygen levels of an intubated COVID-19 patient at the Tactical Care Unit at Parkland Hospital on February 10, 2021 in Dallas .
Source link

Supply chain issues affect local pharmacies Tue, 30 Nov 2021 00:25:24 +0000

HUNTSVILLE, Alabama – Supply chain shortages are everywhere these days. From retail stores to grocery stores, this could now impact your local pharmacy.

Pharmacies in Alabama are running out of prescription drugs. Some of these include heart medications, cancer medications, inhalers, and arthritis pain relievers. Even some contraceptives are late. Your pharmacy is warning you, don’t wait until the last minute to order these life-saving drugs.

“I’ve seen a deadlock on a few inhalers and some other antibiotics have been put on the back burner lately,” says Erin Fehrenbacher, pharmacist for Sparkman Pharmacy.

Sparkman Pharmacy has a few locations in Madison County that have a diverse patient population in their network, so Dr. Fehrenbacher says it’s important to maintain the drug inventory.

“It’s important to keep what we need on hand, to keep control of our inventory to make sure we are serving populations at risk, in need in the community,” Fehrenbacher continued. “We want to make sure that we are doing everything possible to reach all possible patients. ”

Dr Fehrenbacher says customers should keep in mind that most drugs are made overseas and even if this product is left on time, it can present a problem in reaching the patient in a timely manner. The fair warning is to keep ordering in advance.

“If it is something like an antibiotic at the last minute, you may have to shop around the different pharmacies,” Fehrenbacher concluded. “If it’s something like an inhaler that you take regularly, be sure to call your refill ahead of time without waiting until the last minute, so you don’t run out.”

The FDA says there are currently more than 100 drugs that are out of stock. Most pharmacies I’ve spoken to say they don’t expect the stalemate to be over until the end of this year or the start of next year.

Source link

Everything You Need To Know About The Global Supply Chain Crisis, Retail News, ET Retail Mon, 29 Nov 2021 11:24:00 +0000 Global supply chains are creaking. Shortages of everything from raw materials to cars are approaching historic levels. Shipping rates have hit multi-year highs and consumers are facing delays and price increases that will extend beyond the holiday season. Much of the demand is in the United States, where buyers seem to have an endless appetite as the economy makes a comeback.

Meanwhile, the supply is mostly in Asia, where many countries – first and foremost China – still face lockdowns and a difficult recovery from the pandemic. This created tensions between global trade channels, manufacturing centers and logistics networks. How businesses and policymakers overcome these challenges that now weigh on growth will be critical. Bloomberg columnists Brooke Sutherland, Daniel Moss and David Fickling joined Bloomberg Economics’ Tom Orlik to discuss the pressure points and factors at play, the reaction of industrial companies and what consumers need to be prepared for. Here are edited highlights from their conversation, moderated by Bloomberg Opinion’s Anjani Trivedi.

Trivedi: All the demand is in the United States, and a lot of the supply comes from Asia. What have you seen with shipping and logistics on the trade front?
If you look at trade volumes, the trend growth in global trade volumes – which tends to increase at a fairly constant rate – essentially came to a halt in 2018 with Trump’s trade wars. Before the great macroeconomic upheaval of the Covid, there was this macroeconomic upheaval of a kind of rather unprecedented stock in the growth of the volume of trade. There is yet another cycle, these very long cycles of overcapacity and undercapacity that we see in the shipping container industry.

At this point, the global container transport fleet is the oldest since 2008. So they’re really not being sustained even without what’s happening with the Covid rebound. With the shift from services to goods in consumer spending, we still don’t really have a suitable marine fleet or shipping infrastructure for use. The trade slowdown in Trump’s trade wars has covered this to some extent. Now we are looking him in the face.

Trivedi: When we think of the pricing power for American manufacturers, what do we really see in the numbers?
In general, the profit margins were good, and I think a lot of it came down to the pricing power. We just saw some really incredible pricing power from these industrial companies. They have also become very creative in terms of re-routing cargo to less congested ports. One trend that has just started over the past couple of weeks is that we have seen a number of US companies take steps to further integrate their supply chains internally by integrating vertically. One of them that I found really interesting is that American Eagle has acquired two logistics companies, which is very unusual for such a specialty retailer in the United States to buy companies from logistics. But they wanted more control over their operations so they could offer affordable same-day and next-day delivery and compete with Amazon and Walmart, which obviously have much larger logistics operations.

Trivedi: What’s going on on the supply side in China?
What is happening in China right now is really interesting. There are a few factors of work, which contribute to the slowdown in growth in China, but also tensions on world supply. The first is China’s zero Covid strategy. There aren’t many cases of Covid in China, but even when there are one or two in a city, that city is on lockdown. Because China is the largest source of global manufactured goods, this can impact the global economy. When you have energy shortages, it makes it harder for the industry to function, which also contributes to supply tensions.
Everything you need to know about the global supply chain crisisMousse: This supply chain story is as much of an issue in Asia as it is in Western Europe or the United States, with a few caveats. First, the prices of many things are largely controlled by government policy in important parts of Asia. If you are a country like Singapore, even if you are big in logistics, you are big in freight, you are big in port, you are big in transit … In lockdown, these things don’t necessarily work for you. If we can’t get our things back, what are we going to do? This opens up a whole host of existential issues – not just on TVs, refrigerators, and personal computers, but on things as basic as food. Was there a discussion here at the New Economic Forum about how we make sure the vaccine supply chain – absolutely essential to everything – is kept running?

Orlik: The big takeaway is that supply shortages are really at a historically high level. We haven’t seen so much pressure on the supply chain in 10 years – in 20 years in some countries. The second point to remember, and it’s really just kind of a very tentative sign at this point, at least in the US, our gauge shows that supply chain tensions may have peaked. . The peak happened a few months ago. Supply flows are still historically high, but they are not as high as they were at the end of the third quarter.

Trivedi: How does energy play a role in the functioning of supply chains?
All of the ships that ply the seas are all fueled by fuel oil, but this is surprisingly not the biggest factor in the cost of transportation. The place where it really matters is in China itself. For all the major commodities – aluminum, copper, steel, all those industrial qualities that are the very basis of these supply chains – China manufactures roughly 50%. They are very energy intensive. In fact, they are so energy intensive that the Chinese government has made some pretty serious efforts to crack down on these industries. They want to reduce production and above all reduce emissions because of their own goals.

Sutherland: Even though the United States has reopened and been further ahead than some other parts of the world, you can fly today. You can go to the movies and people spend on those things. Bank of America is releasing some very interesting credit card data, and it showed airline spending turned positive on a two-year basis for the first time this year in the past two weeks. Entertainment spending is up about 4% from pre-pandemic levels, and yet we still see insane spending on goods. Furniture spending is still up nearly 35% on a two-year basis, home improvement store spending is up nearly 50%. It’s interesting that even though we’ve seen this reopening trend, the American consumer is still very willing to spend on goods, and this contributes to some of the supply chain challenges we’ve seen.

Trivedi: We’re starting to see corporate spending on solutions increasing. Are there other concrete solutions we need to think about?
What do we need to have more resilient supply chains? Lots of capital investments to diversify sources of supply and strengthen logistics. You need a huge amount of management bandwidth at the enterprise level, leadership bandwidth at the government level to think through these issues, and boots on the ground to start making things happen on the ground. projects.

Trivedi: Should we be ordering Christmas presents right now?
If there is an item that you really want or your kids really want, you should definitely order it ASAP. Part of this is definitely in the retailer’s best interests to get you to buy really quickly. It helps them manage their supply chains. It helps them not to give you a ton of deals this holiday season. If there is one thing you really must have, you definitely should have bought it yesterday. But in general, you will probably be able to find your Christmas presents.

Corban’s Partnership with Free Salem Clinics Meets Critical Mental Health Needs in Salem Mon, 29 Nov 2021 03:08:43 +0000

November 29, 2021